Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

BACKGROUND: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4–6 cycles. The optimal duration of first-line therapy is still un...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Di Bartolomeo, Maria, Niger, Monica, Morano, Federica, Corallo, Salvatore, Antista, Maria, Tamberi, Stefano, Lonardi, Sara, Di Donato, Samantha, Berardi, Rossana, Scartozzi, Mario, Cardellino, Giovanni Gerardo, Di Costanzo, Francesco, Rimassa, Lorenza, Luporini, Alberto Gianluigi, Longarini, Raffaella, Zaniboni, Alberto, Bertolini, Alessandro, Tomasello, Gianluca, Pinotti, Graziella, Scagliotti, Giorgio, Tortora, Giampaolo, Bonetti, Andrea, Spallanzani, Andrea, Frassineti, Giovanni Luca, Tassinari, Davide, Giuliani, Francesco, Cinieri, Saverio, Maiello, Evaristo, Verusio, Claudio, Bracarda, Sergio, Catalano, Vincenzo, Basso, Michele, Ciuffreda, Libero, De Vita, Ferdinando, Parra, Hector Soto, Fornaro, Lorenzo, Caporale, Marta, de Braud, Filippo, Pietrantonio, Filippo
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Study Protocol
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440108/
https://ncbi.nlm.nih.gov/pubmed/30922323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5498-3
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍